GlassScriptPhysician profile
Andrew N Mccall
NPI 1790122299
$4,494.70
in general payments reported to CMS, 2019-2025
39 companies · $522 in 2025
The $522 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $291 · 2021: $458 · 2022: $598 · 2023: $1,025 · 2024: $968 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.04 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $965.66 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $801.36 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $597.38 | 2019-2025 | |
| Allergan, INC. | $300.80 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $216.94 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $200.43 | 2021-2024 | Prolaris |
| Procept Biorobotics Corporation | $191.70 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Janssen Biotech, INC. | $184.79 | 2019-2022 | |
| Urogen Pharma, INC. | $137.50 | 2021-2025 | |
| Urovant Sciences INC | $83.31 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $70.14 | 2022-2023 | Pylarify |
| Stryker Corporation | $66.90 | 2023 | Fluid Management System |
| Pfizer INC. | $61.59 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $56.13 | 2024 | Adstiladrin |
| Antares Pharma, INC. | $52.53 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $52.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Endo Pharmaceuticals INC. | $33.48 | 2019-2024 | Xiaflex, Aveed |
| Mission Pharmacal Company | $31.62 | 2022-2024 | Uribel Tabs |
| Novartis Pharmaceuticals Corporation | $26.48 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.11 | 2019 | |
| Civco Medical Instruments | $22.85 | 2024 | |
| Blue Earth Diagnostics | $21.06 | 2022 | |
| 180 Medical, INC. | $20.31 | 2019 | |
| Agiliti Surgical, INC. | $19.65 | 2019 | |
| Endo USA, INC. | $18.68 | 2024 | Xiaflex, Aveed |
| Ambu INC. | $18.53 | 2022 | |
| Immunitybio, INC. | $18.21 | 2024 | |
| Intuitive Surgical, INC. | $17.68 | 2024 | |
| Neotract INC. | $17.59 | 2019 | |
| Telix Pharmaceuticals | $17.34 | 2024 | Illuccix |
| Tolmar, INC. | $17.31 | 2023 | |
| Axonics, INC. | $16.16 | 2022 | |
| Coloplast Corp | $15.72 | 2024 | |
| Teleflex LLC | $15.49 | 2023 | Urolift |
| Acerus Pharmaceuticals Corporation | $13.58 | 2021 | |
| Ethicon US, LLC | $11.82 | 2020 | |
| Medtronic, INC. | $11.73 | 2022 | |
| Duchesnay USA Incorporated | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.